PT3302454T - Composições para utilização no tratamento da doença de parkinson e distúrbios associados - Google Patents
Composições para utilização no tratamento da doença de parkinson e distúrbios associadosInfo
- Publication number
- PT3302454T PT3302454T PT167344811T PT16734481T PT3302454T PT 3302454 T PT3302454 T PT 3302454T PT 167344811 T PT167344811 T PT 167344811T PT 16734481 T PT16734481 T PT 16734481T PT 3302454 T PT3302454 T PT 3302454T
- Authority
- PT
- Portugal
- Prior art keywords
- disease
- compositions
- related disorders
- treating parkinson
- parkinson
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562166531P | 2015-05-26 | 2015-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3302454T true PT3302454T (pt) | 2021-04-01 |
Family
ID=56322267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167344811T PT3302454T (pt) | 2015-05-26 | 2016-05-25 | Composições para utilização no tratamento da doença de parkinson e distúrbios associados |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10471025B2 (pt) |
| EP (1) | EP3302454B1 (pt) |
| JP (1) | JP6853791B2 (pt) |
| CN (1) | CN107660147B (pt) |
| AU (1) | AU2016266432B2 (pt) |
| CA (1) | CA2986891C (pt) |
| ES (1) | ES2869981T3 (pt) |
| PT (1) | PT3302454T (pt) |
| WO (1) | WO2016190766A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL319386A (en) * | 2018-10-11 | 2025-05-01 | Indivior Uk Ltd | Buprenorphine for the treatment of respiratory depression |
| EP3902539B1 (en) * | 2018-12-24 | 2024-07-31 | Sorrento Therapeutics, Inc. | Methods for treating parkinson's disease by administering resiniferatoxin |
| EP4243801A1 (en) * | 2020-11-10 | 2023-09-20 | Integrative Research Laboratories Sweden AB | [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (mesdopetam) for use in the prevention or reduction of sensitization to a pharmaceutical drug for parkinson's disease, in particular l-dopa induced dyskinesias |
| CN112933117B (zh) * | 2021-04-28 | 2023-04-07 | 遵义医科大学 | 一种预防和/或治疗帕金森病的药物及其应用 |
| JP2024520132A (ja) * | 2021-06-04 | 2024-05-21 | トランスポゾン セラピューティクス インコーポレイテッド | 向知性薬としてのｌｉｎｅ－１阻害剤 |
| CN113422876B (zh) * | 2021-06-24 | 2022-05-10 | 广西电网有限责任公司 | 基于ai的电力客服中心辅助管理方法、系统及介质 |
| WO2023019351A1 (en) * | 2021-08-16 | 2023-02-23 | University Health Network | Methods and compositions for treating alpha-synuclein-mediated neurodegeneration |
| CN116832066B (zh) * | 2023-08-08 | 2024-01-12 | 青岛海洋生物医药研究院股份有限公司 | 乌贼墨提取物在制备抗多动症和抗抑郁症药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6071970A (en) | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| PT1539135E (pt) * | 2002-09-17 | 2007-07-12 | Motac Neuroscience Ltd | Tratamento da discinesia. |
| WO2008079404A2 (en) | 2006-12-22 | 2008-07-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
| EP1985292A1 (en) * | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
| PL2596784T3 (pl) * | 2007-11-23 | 2017-06-30 | Grünenthal GmbH | Kompozycje tapentadolu |
| WO2009147681A1 (en) | 2008-06-06 | 2009-12-10 | Pharma Two B Ltd. | Pharmaceutical compositions for treatment of parkinson's disease |
| US8288592B2 (en) | 2009-09-22 | 2012-10-16 | Actavis Group Ptc Ehf | Solid state forms of tapentadol salts |
| US20140037729A1 (en) * | 2010-12-28 | 2014-02-06 | Euro-Celtique, S.A. | Combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease |
| WO2012136351A1 (en) * | 2011-04-05 | 2012-10-11 | Grünenthal GmbH | Tapentadol for treating pain associated with trigeminal neuralgia |
| PT2701693T (pt) * | 2011-04-29 | 2017-11-16 | Gruenenthal Gmbh | Tapentadol para prevenção e tratamento de depressão e ansiedade |
| KR20240004497A (ko) * | 2013-03-15 | 2024-01-11 | 멜리어 파마슈티칼스 투, 엘엘씨. | 시드노카브 또는 이의 약학적으로 허용되는 염을 포함하는 약학적 조성물 및 수면 장애를 치료하는 방법 |
-
2016
- 2016-05-25 US US15/568,655 patent/US10471025B2/en active Active
- 2016-05-25 PT PT167344811T patent/PT3302454T/pt unknown
- 2016-05-25 EP EP16734481.1A patent/EP3302454B1/en active Active
- 2016-05-25 WO PCT/PT2016/050010 patent/WO2016190766A1/en not_active Ceased
- 2016-05-25 AU AU2016266432A patent/AU2016266432B2/en active Active
- 2016-05-25 CA CA2986891A patent/CA2986891C/en active Active
- 2016-05-25 JP JP2017559872A patent/JP6853791B2/ja active Active
- 2016-05-25 ES ES16734481T patent/ES2869981T3/es active Active
- 2016-05-25 CN CN201680030076.6A patent/CN107660147B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018515549A (ja) | 2018-06-14 |
| CA2986891A1 (en) | 2016-12-01 |
| AU2016266432B2 (en) | 2020-10-22 |
| CN107660147B (zh) | 2021-04-30 |
| WO2016190766A1 (en) | 2016-12-01 |
| CA2986891C (en) | 2022-01-04 |
| EP3302454A1 (en) | 2018-04-11 |
| EP3302454B1 (en) | 2021-03-10 |
| CN107660147A (zh) | 2018-02-02 |
| ES2869981T3 (es) | 2021-10-26 |
| US20180147160A1 (en) | 2018-05-31 |
| US10471025B2 (en) | 2019-11-12 |
| JP6853791B2 (ja) | 2021-03-31 |
| AU2016266432A1 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274648A (en) | Promote new catecholamine drugs for use in the treatment of Parkinson's disease | |
| LT3889145T (lt) | 8-ciano-5-piperidin-chinolinai, kaip tlr7/8 antagonistai ir jų panaudojimas gydant imuninius sutrikimus | |
| PT3302454T (pt) | Composições para utilização no tratamento da doença de parkinson e distúrbios associados | |
| IL277182A (en) | Compositions and methods for treating Parkinson's disease | |
| IL263188B (en) | Treatment for Parkinson's disease | |
| AU2022271491B2 (en) | Antisense oligonucleotides for use in treating alzheimer's disease | |
| SMT202200151T1 (it) | Composizioni e metodi per l’uso nel trattamento di omocistinuria. | |
| IL265911A (en) | Epilimod preparations and methods of using them in the treatment of Alzheimer's disease | |
| EP3554496A4 (en) | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | |
| IL254252A0 (en) | History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease | |
| IL274203A (en) | A pharmaceutical solution containing dopamine for use in the treatment of Parkinson's disease | |
| PL3352742T3 (pl) | Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona | |
| IL265656A (en) | Preparations and methods for the treatment of Alzheimer's disease and Parkinson's disease | |
| EP3256151A4 (en) | Methods and compositions for treating muscle disease and disorders | |
| EP3162377A4 (en) | Use of -asarone in preparing drugs for preventing and treating alzheimer's disease | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| ZA201806894B (en) | (+)-azasetron for use in the treatment of ear disorders | |
| GB201603510D0 (en) | Compositions for use in the treatment of neurological disease | |
| SG11201701618SA (en) | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders | |
| ZA201807944B (en) | Treatment for parkinson's disease | |
| HK40012465A (en) | Compositions and methods for treating alzheimer's disease and parkinson's disease | |
| GB201518052D0 (en) | Parkinson's disease treatment | |
| HK40013419A (en) | Apilimod compositions and methods for using same in the treatment of alzheimer's disease | |
| PT3442537T (pt) | (+)-azasetrom para utilização no tratamento de doenças do ouvido | |
| GB201504144D0 (en) | Treatment of Parkinson's disease |